BSX
Boston Scientific Corporation
BSX offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY
Eli Lilly and Company
LLY has the edge over BSX overall, supported by stronger modeled upside and stronger fundamentals.
BSX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Stable |
BSX's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BSX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $44.20 | — |
| Cheap | 18x | $43.27 | -2.1% |
| Current | 19x | $44.20 | — |
| Fair | 64x | $151 | +241% |
| Expensive | 90x | $211 | +378% |
Historical ranges are pointers, not guarantees.
BSX has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BSX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Stable | |
| Stable | |
| Moderate | |
| High |
Analysts expect BSX's earnings, revenue and profitability to hold roughly steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over BSX on the outlook, with more favorable earnings and revenue expectations.
BSX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.09 | +31% |
| Q3 2026 | $2.36 | +26% |
| Q2 2026 | $2.47 | +47% |
| Q1 2026 | $2.39 | +74% |
| Q4 2025 | $1.94 | +55% |
| Q3 2025 | $1.87 | +55% |
| Q2 2025 | $1.68 | +37% |
| Q1 2025 | $1.37 | +15% |
| Q4 2024 | $1.25 | +17% |
BSX's earnings per share have fallen from their peak: $2.36 over the past year, against $3.33 in late 2019.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BSX on earnings, with stronger typical year-over-year growth.
BSX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +1.4% |
| Q2 2026 | $5.4B | +7.5% |
| Q1 2026 | $5.2B | +12% |
| Q4 2025 | $5.3B | +16% |
| Q3 2025 | $5.1B | +20% |
| Q2 2025 | $5.1B | +23% |
| Q1 2025 | $4.7B | +21% |
| Q4 2024 | $4.6B | +22% |
BSX's revenue has grown year over year for 23 quarters in a row: $5.1B last quarter, up 1.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -4.6 points |
| Q2 2026 | 22% | +5.5 points |
| Q1 2026 | 21% | +1.4 points |
| Q4 2025 | 16% | +0.8 points |
| Q3 2025 | 21% | +3.3 points |
| Q2 2025 | 16% | +3.6 points |
| Q1 2025 | 20% | +2.2 points |
| Q4 2024 | 15% | -0.9 points |
BSX's operating margin was 16% last quarter, down 4.6 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BSX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BSX on profitability, with a higher operating margin.
BSX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $868M | -25% |
| Q2 2026 | $1.3B | +13% |
| Q1 2026 | $171M | -52% |
| Q4 2025 | $1B | -14% |
| Q3 2025 | $1.2B | +41% |
| Q2 2025 | $1.1B | +72% |
| Q1 2025 | $354M | +$369M |
| Q4 2024 | $1.2B | +71% |
BSX generated $3.3B in free cash flow over the past year, down 13% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BSX on cash flow, with more consistent year-over-year improvement.
BSX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -22.8M shares |
| 1 year | -2.9% | -43.5M shares |
| 3 years | -1.6% | -23M shares |
| 5 years | +1.1% | +16.4M shares |
| Available history | +2.9% | +41.4M shares |
BSX has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BSX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.2x | Moderate |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 2.5x | Moderate |
| Q1 2025 | 2.6x | Moderate |
| Q4 2024 | 2.7x | Moderate |
BSX's net debt is about 2.1 years of its operating earnings (EBITDA), about the same as a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over BSX on leverage, with a lower net debt burden relative to earnings.
BSX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.6 | Neutral |
| Stochastic | 25.4 | Neutral |
BSX's weekly RSI is 40 (neutral) and its Stochastic is 25 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BSX PE vs Healthcare Sector
| Metric | BSX | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 26x | 28% below |
| PE % | 17 | 29 | 12 pts below |
BSX has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BSX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $43.5 | 1.5% above |
| 20 week MA | $45.3 | 2.4% below |
| 50 week MA | $60.8 | 27% below |
| 100 week MA | $80.8 | 45% below |
| 200 week MA | $72.2 | 39% below |
BSX has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 39% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BSX on trend strength, trading above more of its moving averages.
BSX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $45.2 | $34.6 | -24% |
| 2021 | $34.6 | $42.7 | +24% |
| 2022 | $42.7 | $46.1 | +7.8% |
| 2023 | $46.1 | $57.8 | +26% |
| 2024 | $57.8 | $90.7 | +57% |
| 2025 | $90.7 | $96.1 | +6% |
| 2026 YTD | $96.1 | $44.2 | -54% |
BSX is down 54% so far in 2026, after finishing higher in five of the previous six years.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BSX on returns for 2026, with the stronger performance.